Table 2 Numbers of patients treated with a cellular therapy in Europe 2019 by indication, donor type and cell source.

From: Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

Number of patients DLI CART MSC NK cells Selected/expanded T cells or CIK Regulatory T cells (TREGS) Genetically modified T cells Dendritic cells Expanded CD34+ cells Genetically modified CD34+ cells Other Total excl DLI
2019   Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto allo auto
GvHD     296   1   1   48           9 1 355 1
Graft enhancement     20   1   22         7 1 1   173 27 224 28
Autoimmune dis.     24 8           3     4   3 24 18
Genetic disease     1                14 1 2 2 16
Infection     4     203 9 1   5 1        37   250 10
Malignancy—ALL   20 232 4   2   4     4    6      2 1 36 239
Malignancy—HL/NHL    826    1   3              4 4 830
Malignancy—other   1 55 1 1 8   14 21 13   2 1   25     4 20 11 59 118
DLI for graft enhancement/failure 716                      0 0
DLI for residual disease 431                      0 0
DLI for relapse 1461                      0 0
DLI per protocol 420                      0 0
Total 3028 21 1113 350 9 13 0 247 30 62 0 11 2 0 34 7 1 1 22 242 49 954 1260